Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function

Completed · Phase 1

Conditions studied: Renal Impairment

In brief

A study to evaluate the pharmacokinetics of CP-690,550 in subjects with mild, moderate or severe renal impairment, who do not require hemodialysis, compared to healthy controls.

Key facts

Study ID

NCT01740362

Run by

Pfizer

People needed

24

Starts

2003-10-01

Expected to finish

2004-03-01

Last updated by the study team

2013-01-07

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subjects with normal renal function: Subjects must be healthy with estimated creatinine clearance >80 mL/min
• Subjects with renal impairment: Subjects should be in good general health commensurate with the population with chronic kidney disease

You may not qualify if…

• Kidney transplant patients
• Subjects with any condition possibly affecting drug absorption
• Subjects with malignancies with the exception of adequately treated basal cell carcinoma of the skin

Where it is running

• Pfizer Investigational Site — Orlando, Florida, United States
• Pfizer Investigational Site — New Orleans, Louisiana, United States
• Pfizer Investigational Site — New Orleans, Louisiana, United States
• Pfizer Investigational Site — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.